Updated Data from Part A of Verastem Oncology's RAMP 201 Trial Show an Objective Response Rate of 45% in Patients with Recurrent Low-Grade Serous Ovarian Cancer Treated with Avutometinib and DefactinibBusiness Wire • 05/25/23
Verastem Oncology Reports First Quarter 2023 Financial Results and Highlights Recent Company ProgressBusiness Wire • 05/09/23
New Data from Interim Analysis of Verastem Oncology's RAMP 201 Trial Evaluating Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at the American Society of Clinical Oncology Annual MeetingBusiness Wire • 04/26/23
Verastem Oncology to Present at the Stifel 2023 Virtual Targeted Oncology DaysBusiness Wire • 04/18/23
New Verastem Oncology Initiative, Let's Talk About LGSOC, Calls Attention to Rare Form of Ovarian CancerBusiness Wire • 03/15/23
Verastem Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company ProgressBusiness Wire • 03/14/23
Verastem Oncology Outlines Key 2023 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib as a Backbone of Therapy for RAS Pathway-Driven CancersBusiness Wire • 02/02/23
Verastem (VSTM) Upgraded to Strong Buy: What Does It Mean for the Stock?Zacks Investment Research • 01/30/23
Verastem Oncology Announces Up to $60 Million Private Placement Offering of Series B Convertible Preferred StockBusiness Wire • 01/24/23
Verastem Oncology Announces Positive Data and Regulatory Update from Planned Interim Analysis of Registration-Directed Phase 2 RAMP-201 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian CancerBusiness Wire • 01/24/23
Verastem Oncology Reports Third Quarter 2022 Financial Results and Highlights Recent Company ProgressBusiness Wire • 11/03/22
Verastem Oncology Announces RAMP VS-6766 Clinical Trials and Corporate UpdatesBusiness Wire • 10/04/22
Verastem Oncology Reports Second Quarter 2022 Financial Results and Highlights Recent Company ProgressBusiness Wire • 08/08/22
Verastem Oncology Provides Update on RAMP 201 Study Evaluating VS-6766 ± Defactinib in Low-Grade Serous Ovarian CancerBusiness Wire • 06/06/22
Verastem Oncology Awarded Pancreatic Cancer Action Network's First Therapeutic Accelerator Award to Evaluate the Combination of VS-6766 and Defactinib in Front-Line Metastatic Pancreatic CancerBusiness Wire • 05/18/22
Verastem Oncology Reports First Quarter 2022 Financial Results and Highlights Recent Company ProgressBusiness Wire • 05/09/22